Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling

mAbs

Volumn 6, Issue 3, 2014, Pages 774-782

  Shaw, Stevan ^a   Bourne, Tim ^a   Meier, Chris ^a   Carrington, Bruce ^a   Gelinas, Rich ^b   Henry, Alistair ^a   Popplewell, Andrew ^a   Adams, Ralph ^a   Baker, Terry ^a   Rapecki, Steve ^a   Marshall, Diane ^a   Moore, Adrian ^a   Neale, Helen ^a   Lawson, Alastair ^a  

^a UCB PHARMA   (Belgium)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

Antibody; gp130; IL 6; Interleukin 6; Neutralization; Olokizumab; Site 3; Structure

Indexed keywords

C REACTIVE PROTEIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; OLOKIZUMAB; SERUM AMYLOID A; STAT3 PROTEIN; ANTIGEN ANTIBODY COMPLEX; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; CYTOLOGY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VIVO STUDY; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIGEN ANTIBODY COMPLEX; ARTHRITIS, EXPERIMENTAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HYBRIDOMA; IMMUNOLOGY; MACACA FASCICULARIS; MOLECULAR GENETICS; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS, EXPERIMENTAL; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYTOKINE RECEPTOR GP130; FEMALE; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN FAB FRAGMENTS; INTERLEUKIN-6; MACACA FASCICULARIS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RATS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84899708467     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28612     Document Type: Article

References (55)

1. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2012; 122:143-59; PMID:22029668; http://dx.doi.org/10.1042/CS20110340
2. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4(Suppl 3):S233-42; PMID:12110143; http://dx.doi.org/10.1186/ar565
3. Assier E, Boissier M-C, Dayer J-M. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010; 77:532-6; PMID:20869898; http://dx.doi.org/10.1016/j.jbspin.2010.07.007
4. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121:3375-83; PMID:21881215; http://dx.doi.org/10.1172/JCI57158
5. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813:878-88; PMID:21296109; http://dx.doi.org/10.1016/j.bbamcr.2011.01. 034
6. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300:2101-4; PMID:12829785; http://dx.doi.org/10.1126/science.1083901
7. Somers W, Stahl M, Seehra JS. 1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J 1997; 16:989-97; PMID:9118960; http://dx.doi.org/10.1093/emboj/16.5.989
8. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012; 8:1237-47; PMID:23136552; http://dx.doi.org/10.7150/ijbs.4989
9. Veverka V, Baker T, Redpath N, Carrington B, Muskett F, Taylor R, et al. Conservation of functional sites on interleukin-6 and implications for evolution of signalling complex assembly. J Biol Chem 2012; 287:40043-50; PMID:23027872; http://dx.doi.org/10.1074/jbc.M112.405597
10. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010; 49:15-24; PMID:19854855; http://dx.doi.org/10.1093/rheumatology/kep329
11. Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP, Verweij CL. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004; 63:233-9; PMID:14962955; http://dx.doi.org/10.1136/ard.2003.013276
12. Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol 2012; 2012:946048; PMID:22315615; http://dx.doi.org/10.1155/2012/946048
13. Gross V, Andus T, Caesar I, Roth M, Schölmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102:514-9; PMID:1370661
14. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62:542-52; PMID:20112381; http://dx.doi.org/10.1002/art.27221
15. Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011; 2011:432595; PMID:22028588; http://dx.doi.org/10.1155/2011/432595
16. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 2008; 47:1635-40; PMID:18786965; http://dx.doi.org/10.1093/rheumatology/ken363
17. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3:390-407; PMID:16819502; http://dx.doi.org/10.1038/ncpgasthep0528
18. Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, Harada K, Tateishi H, Nishiyama T, Tanikawa K. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995; 36:45-9; PMID:7890234; http://dx.doi.org/10.1136/gut.36.1.45
19. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13:339-43; PMID:15230289; http://dx.doi.org/10.1191/0961203304lu1023oa
20. Takeno M, Nagafuchi H, Kaneko S, Wakisaka S, Oneda K, Takeba Y, Yamashita N, Suzuki N, Kaneoka H, Sakane T. Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. J Immunol 1997; 158:3529-38; PMID:9120315
21. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-24; PMID:10500098; http://dx.doi.org/10.1101/gad.13.18.2412
22. Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int 2009; 29:1449-54; PMID:19277666; http://dx.doi.org/10.1007/s00296-009-0885-8
23. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003; 48:1521-9; PMID:12794819; http://dx.doi.org/10.1002/art.11143
24. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583-8; PMID:10802717; http://dx.doi.org/10.1038/75068
25. Burmester G, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, et al. A randomized, double-blind, parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional Dmards in patients with moderate to severe RA. Arthritis Rheum 2012; 64:S1075
26. Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, Huang X, Yancopoulos GD, Stahl N, Genovese MC. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2013; http://dx.doi.org/10.1136/annrheumdis-2013-204405; PMID:24297381; http://dx.doi.org/10.1136/annrheumdis-2013-204405
27. Holtz J-B. oral presentation at EULAR 2013 http://www.ablynx.com/wp- content/uploads /2013/06/ALX-0061-at-EULAR-2013-beyond-TNF.pdf
28. Fleischmann R, Kivitz A, Wagner F, Feinstein J, Fuhr U, Rech J, et al. A pilot study investigating the tolerability and pharmacodynamc effect of single intravenous/subcutaneous dises of olokizumab, an anti-interleukin-6 monoclonal antibody, in patients with rheumatoid arthritis. Arthritis and Rheumatism 2012; 64: Abstract supplement of the American College of Rheumatology/Association of Rheumatology Professionals Annual Scientific Meeting. Washington, DC November 9-14th 2012.
29. Hsu B, Sheng S, Smolen J, Weinblatt M. Results from a 2-part, proof of concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy. Arthritis and Rheumatoid 2011; Abstract 2631, 75th Annual Meeting of ACR/ARHP, 5-9th November, Chicago.
30. Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012; 48:85-93; PMID:22129890; http://dx.doi.org/10.1016/j.ejca.2011.10.014
31. Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012; 71:1183-9; PMID:22328739; http://dx.doi.org/10.1136/annrheumdis-2011-200704
32. Katzka DA, Loftus EV Jr., Camilleri M. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases. Clin Pharmacol Ther 2012; 92:306-20; PMID:22828717; http://dx.doi.org/10.1038/clpt.2012.77
33. Silverman J, Liu Q, Bakker A, To W, Duguay A, Alba BM, Smith R, Rivas A, Li P, Le H, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005; 23:1556-61; PMID:16299519; http://dx.doi.org/10.1038/nbt1166
34. Mees ST, Toellner S, Marx K, Faendrich F, Kallen KJ, Schroeder J, Haier J, Kahlke V. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis. J Surg Res 2009; 157:235-42; PMID:19589542; http://dx.doi.org/10.1016/j.jss.2008.08.035
35. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007; 372:774-97; PMID:17681537; http://dx.doi.org/10.1016/j.jmb.2007.05.022
36. Bhat TN, Bentley GA, Boulot G, Greene MI, Tello D, Dall'Acqua W, Souchon H, Schwarz FP, Mariuzza RA, Poljak RJ. Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc Natl Acad Sci U S A 1994; 91:1089-93; PMID:8302837; http://dx.doi.org/10.1073/pnas.91.3.1089
37. Lindsay MA. Target discovery. Nat Rev Drug Discov 2003; 2:831-8; PMID:14526386; http://dx.doi.org/10.1038/nrd1202
38. Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009; 157:220-33; PMID:19459844; http://dx.doi.org/10.1111/j.1476-5381.2009.00190.x
39. Sela-Culang I, Alon S, Ofran Y. A systematic comparison of free and bound antibodies reveals binding-related conformational changes. J Immunol 2012; 189:4890-9; PMID:23066154; http://dx.doi.org/10.4049/jimmunol.1201493
40. Cepica A, Yason C, Ralling G. The use of ELISA for detection of the antibody-induced conformational change in a viral protein and its intermolecular spread. J Virol Methods 1990; 28:1-13; PMID:2112149; http://dx.doi.org/10.1016/ 0166-0934(90)90082-Q
41. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10. 1038/nature01392
42. Oyen D, Srinivasan V, Steyaert J, Barlow JN. Constraining enzyme conformational change by an antibody leads to hyperbolic inhibition. J Mol Biol 2011; 407:138-48; PMID:21238460; http://dx.doi.org/10.1016/j.jmb.2011.01.017
43. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A 1996; 93:7843-8; PMID:8755564; http://dx.doi.org/10.1073/pnas.93.15.7843
44. Tickle S, Adams R, Brown D, Griffiths M, Lightwood D, Lawson A. High-throughput screening for high affinity antibodies. J of Laboratory Automation 2009; 14:303-7; http://dx.doi.org/10.1016/j.jala.2009.05.004
45. Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233:566-9; PMID:3726549; http://dx.doi.org/10.1126/science.3726549
46. Kabat E, Wu T, Reid-Miller M, Perry H, Gottesman K. Sequences of proteins of immunological interest. US Dept of Health and Human Services, Public Health Service National Institutes of Health; 1987.
47. Adair JR. Engineering antibodies for therapy. Immunol Rev 1992; 130:5-40; PMID:1286872; http://dx.doi.org/10.1111/j.1600-065X.1992.tb01519.x
48. Mason M, Sweeney B, Cain K, Stephens P, Sharfstein ST. Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in Chinese hamster ovary cells. Biotechnol Prog 2012; 28:846-55; PMID:22467228; http://dx.doi.org/10.1002/btpr.1542
49. Leslie AG. Integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 1999; 55:1696-702; PMID:10531519; http://dx.doi.org/10.1107/S090744499900846X
50. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007; 40:658-74; PMID:19461840; http://dx.doi.org/10.1107/S0021889807021206
51. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997; 53:240-55; PMID:15299926; http://dx.doi.org/10.1107/S0907444996012255
52. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126-32; PMID:15572765; http://dx.doi.org/10.1107/S0907444904019158
53. DeLano W. The PyMOL Molecular Graphics System. 2002; www.pymol.org
54. Burmeister WP. Structural changes in a cryo-cooled protein crystal owing to radiation damage. Acta Crystallogr D Biol Crystallogr 2000; 56:328-41; PMID:10713520; http://dx.doi.org/10.1107/S0907444999016261
55. rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 2010; 66:12-21; PMID:20057044;; http://dx.doi.org/10.1107/ S0907444909042073